ES2168098T3 - Interleucina-8 marcada y sus utilizaciones medicas. - Google Patents

Interleucina-8 marcada y sus utilizaciones medicas.

Info

Publication number
ES2168098T3
ES2168098T3 ES93923789T ES93923789T ES2168098T3 ES 2168098 T3 ES2168098 T3 ES 2168098T3 ES 93923789 T ES93923789 T ES 93923789T ES 93923789 T ES93923789 T ES 93923789T ES 2168098 T3 ES2168098 T3 ES 2168098T3
Authority
ES
Spain
Prior art keywords
marcada
interleucina
medical uses
target site
labelled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923789T
Other languages
English (en)
Inventor
Leon R Lyle
Steven L Kunkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2168098T3 publication Critical patent/ES2168098T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nuclear Medicine (AREA)
  • Measurement Of Radiation (AREA)

Abstract

UN METODO DE REPRESENTACION DE IMAGENES DE UN LUGAR OBJETIVO EN UN CUERPO DE ANIMAL EN EL QUE SE INTRODUCE QUIMIOCINA CXC MARCADA DENTRO DEL CUERPO DEL ANIMAL Y SE PERMITE QUE SE ACUMULE EN UN LUGAR OBJETIVO QUE INCLUYE MOLECULAS RECEPTORAS DE INTERLEUCINA-8. LA QUIMIOCINA CXC MARCADA ACUMULADA LUEGO SE DETECTA CON OBJETO DE DETECTAR EL LUGAR OBJETIVO DEL CUERPO.
ES93923789T 1992-10-05 1993-10-04 Interleucina-8 marcada y sus utilizaciones medicas. Expired - Lifetime ES2168098T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/956,863 US5346686A (en) 1992-10-05 1992-10-05 Labelled interleukin-8 and medical uses thereof

Publications (1)

Publication Number Publication Date
ES2168098T3 true ES2168098T3 (es) 2002-06-01

Family

ID=25498784

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923789T Expired - Lifetime ES2168098T3 (es) 1992-10-05 1993-10-04 Interleucina-8 marcada y sus utilizaciones medicas.

Country Status (11)

Country Link
US (1) US5346686A (es)
EP (1) EP0670736B1 (es)
JP (1) JPH08511765A (es)
AT (1) ATE205728T1 (es)
AU (1) AU686119B2 (es)
CA (1) CA2146239C (es)
DE (1) DE69330794T2 (es)
DK (1) DK0670736T3 (es)
ES (1) ES2168098T3 (es)
PT (1) PT670736E (es)
WO (1) WO1994007535A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
US5981230A (en) * 1994-08-23 1999-11-09 Human Genome Sciences, Inc. Polynucleotide encoding chemokine β-4
US6458349B1 (en) * 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US5789539A (en) * 1994-10-26 1998-08-04 Repligen Corporation Chemokine-like proteins and methods of use
WO1996024668A1 (en) * 1995-02-08 1996-08-15 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
US6139832A (en) * 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US6410268B1 (en) * 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
NZ332318A (en) * 1996-03-19 2000-10-27 Human Genome Sciences Inc Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
ES2322975T3 (es) * 1998-01-15 2009-07-02 Center For Molecular Medicine And Immunology Componente direccionador biespecifico que comprende un anticuerpo contra el antigeno carcinoembrionario (cea) y la region de union a ligando de la subunidad alfa del receptor de il-13.
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU2007201759B2 (en) * 1998-07-22 2008-05-29 Osprey Pharmaceuticals Usa, Inc. Conjugates for treating inflammatory disorders and associated tissue damage
ES2205849T3 (es) * 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2003092597A2 (en) * 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
EP1437145A1 (en) * 2003-01-07 2004-07-14 Schering AG Enhanced scintigraphic imaging agents for imaging of infection and inflammation
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
GB8525974D0 (en) * 1985-10-22 1985-11-27 Nyegaard & Co As Chemical substance
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
US4732974A (en) * 1986-03-05 1988-03-22 Mallinckrodt, Inc. Metal ion labeling of carrier molecules
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
ATE106898T1 (de) * 1987-03-26 1994-06-15 Neorx Corp Metall-radionuklid-markierte proteine und glykoproteine zur diagnose und therapie.
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
NZ233601A (en) * 1989-05-09 1997-06-24 Gen Hospital Corp N-terminal acylated peptides having an initial sequence met (or nle) -leu-phe and having a detectable label bound through dtpa or edta to a c-terminal lys or pu residue
ES2070329T3 (es) * 1989-07-20 1995-06-01 Sandoz Ltd Derivados de polipeptidos.
EP0504257A4 (en) * 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
WO1991008483A1 (en) * 1989-11-29 1991-06-13 Brigham And Women's Hospital Endothelial-derived il-8
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Also Published As

Publication number Publication date
WO1994007535A2 (en) 1994-04-14
DE69330794T2 (de) 2002-05-23
CA2146239A1 (en) 1994-04-14
AU5353194A (en) 1994-04-26
JPH08511765A (ja) 1996-12-10
AU686119B2 (en) 1998-02-05
US5346686A (en) 1994-09-13
WO1994007535A3 (en) 1994-05-11
DK0670736T3 (da) 2001-11-05
ATE205728T1 (de) 2001-10-15
CA2146239C (en) 2003-04-01
EP0670736A1 (en) 1995-09-13
EP0670736B1 (en) 2001-09-19
DE69330794D1 (de) 2001-10-25
PT670736E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
ES2168098T3 (es) Interleucina-8 marcada y sus utilizaciones medicas.
DE69309479D1 (de) Markiertes monocyte-chemoattractant-proteinmaterial und medizinische anwendung
EA199800733A1 (ru) Антагонисты рецептора il-8
FR2611729B1 (fr) Procede de preparation d'un organopolysiloxane a fonction acrylate et/ou methacrylate
FR2615289B1 (fr) Procede de determination de la natremie d'un patient et rein artificiel en faisant application
NO150015C (no) Fremgangsmaate ved blodstroemhastighetsmaaling med ultralyd, kombinert med ekko-amplitudeavbildning, for undersoekelse av levende biologiske strukturer
IT8149076A0 (it) Sistema di elettrodi fisiologici per la rivelazione di segnali dal corpo umano
FI912050A0 (fi) Menetelmä ihmisen papilloomaviruksen (HPV) toteamiseksi diagnostista käyttöä varten
ES8607020A1 (es) Acidos 1-ciclopropilquinolon-3-carboxilicos
DE3683900D1 (de) Blutstroemung-ultraschallabbildungsgeraet.
NL185964C (nl) Computersysteem met omzetting van de instelling van computercommando's.
IT8423926A0 (it) Metodo diagnostico per la valutazione di parametri clinici mediante prelievo diretto dimateriali biologici e dispositivoper la sua attuazione.
FR2562667B1 (fr) Dispositif combine d'etancheite et de retenue pour epreuve de tubes par fluide sous pression
FR2616914B1 (fr) Dispositif d'analyse par ultrasons
FR2620439B1 (fr) Procede et dispositif de traitement par fermentation methanique d'eaux residuaires lipidiques
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
FR2677449B1 (fr) Procede et dispositif d'etalonnage de couplemetres et couplemetre compact adapte au dispositif.
DE59405299D1 (de) Verfahren zur Herstellung von 2-substituierten 5-Chlorimidazol-4-carbaldehyden
ITMI922243A0 (it) Metodo per l'espressione nel lievito schizosaccharomyces pompe di recettori del sistema nervoso umano
IT8024877A0 (it) Reagente e metodo per determinare l'aldolasi di tipo muscolare umano.
FR2664152B1 (fr) Dispositif d'etude de la mobilite de la colonne vertebrale.
BE878797A (fr) Procede et dispositif de determination des caracteristiques d'occlusion dentaire
FR2643369B1 (fr) La (+) 1-((3,4,5-trimethoxy) benzyloxymethyl)-1-phenyl-n,n-dimethyl-n-propylamine, son procede de preparation et son application en therapeutique
EP0627683A3 (en) System and method adaptable to the user.
IT8120117A0 (it) Reagente e metodo per determinare l'aldolasi di tipo muscolare umano.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 670736

Country of ref document: ES